Ulanowska Magdalena, Olas Beata
Department of General Biochemistry, University of Lodz, Pomorska 141/3, 90-236 Lodz, Poland.
Pathogens. 2021 Mar 19;10(3):370. doi: 10.3390/pathogens10030370.
Although the precise pathogenesis of coronavirus disease 2019 (COVID-19) currently remains unknown, its complex nature is gradually being revealed. COVID-19 is a disease caused by the SARS-CoV-2 virus and leads to respiratory dysfunction. Studies on hemostatic parameters have showed that COVID-19 significantly affects the disruption of the coagulation system and may contribute to coagulation and thrombotic events. A relevant cause of hemostasis disorders is inflammation and cytokine storms, which cause, for example, endothelial dysfunction in blood vessels. In order to prevent and treat states of hypercoagulability and thrombosis, the administration of anticoagulants, e.g., heparin, is recommended. The present mini-review describes the relationship between hemostasis and COVID-19, and discusses whether this relationship may cast light on the nature of COVID-19. The present short manuscript also examines the relationship between blood platelets and COVID-19. In addition, the paper explores the potential use of antiplatelet drugs in COVID-19 cases. The studies were identified by searching electronic databases, including PubMed and SCOPUS.
尽管2019冠状病毒病（COVID-19）的确切发病机制目前仍不清楚，但其复杂的性质正逐渐被揭示。COVID-19是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒引起的疾病，会导致呼吸功能障碍。关于止血参数的研究表明，COVID-19会显著影响凝血系统的紊乱，并可能导致凝血和血栓形成事件。止血障碍的一个相关原因是炎症和细胞因子风暴，例如，它们会导致血管内皮功能障碍。为了预防和治疗高凝状态和血栓形成，建议使用抗凝剂，如肝素。本综述描述了止血与COVID-19之间的关系，并讨论了这种关系是否有助于揭示COVID-19的本质。本简短手稿还研究了血小板与COVID-19之间的关系。此外，本文探讨了抗血小板药物在COVID-19病例中的潜在用途。这些研究是通过搜索电子数据库（包括PubMed和SCOPUS）确定的。
